Avenue Therapeutics, Inc. (ATXI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Alexandra MacLean.
ATXI 을(를) 보유 IPO 날짜 2017-06-27, 2 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $1.68M.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
